AU2012202459B2 — Novel compounds as opioid receptor modulators
Assigned to Janssen Pharmaceutica NV · Expires 2014-06-12 · 12y expired
What this patent protects
Abstract The present invention is directed to novel opioid receptor modulators of Formula: (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated …
USPTO Abstract
Abstract The present invention is directed to novel opioid receptor modulators of Formula: (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors. Figure 1 Figure Recording distensions @ 4 min intervals 0 minutes 202 ~ distensionl pressures: 40 40 60 80 40 60 80 40 60 80 (mmeHg) inutwnnc EMG recordings bathe ositinned (distension timn - 20 see) Zymosan teatment 0 hours 4 5 6 t t t t I m]L ynman A record treat with record (25 mSImI in 30Y. EiOH compound intincolonic admnisrnxlon
Drugs covered by this patent
- Viberzi (ELUXADOLINE) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.